MX2017008410A - Reduccion selectiva de residuos cisteina en anticuerpos il-17. - Google Patents
Reduccion selectiva de residuos cisteina en anticuerpos il-17.Info
- Publication number
- MX2017008410A MX2017008410A MX2017008410A MX2017008410A MX2017008410A MX 2017008410 A MX2017008410 A MX 2017008410A MX 2017008410 A MX2017008410 A MX 2017008410A MX 2017008410 A MX2017008410 A MX 2017008410A MX 2017008410 A MX2017008410 A MX 2017008410A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- secukinumab
- preparation
- antigen binding
- binding fragments
- Prior art date
Links
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 4
- 229960004540 secukinumab Drugs 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 238000005251 capillar electrophoresis Methods 0.000 abstract 1
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 abstract 1
- 238000005341 cation exchange Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación se refiere a métodos para reducir selectivamente CysL97 en una preparación de anticuerpos IL-17 o fragmentos de unión a antígeno de los mismos (p. ej., una preparación de anticuerpos secukinumab), que ha sido producida de forma recombinante por células de mamíferos. También se proporcionan preparaciones purificadas de anticuerpos IL-17 o fragmentos de unión a antígeno de los mismos producidos por estos métodos, p. ej., preparaciones purificadas de secukinumab, en donde el nivel de anticuerpos IL-17 intactos o fragmentos de unión a antígeno de los mismos (p. ej., secukinumab) en la preparación es alto, p. ej., al menos aproximadamente 90%, tal como se mide mediante electroforesis capilar con dodecil-sulfato de sodio (CE-SDS) y en donde el nivel de actividad de anticuerpos IL-17 o fragmentos de unión a antígeno de los mismos (p. ej., secukinumab) en la preparación es alta, p. ej., al menos aproximadamente 92%, tal como se mide mediante cromatografía de intercambio catiónico (CEX).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095361P | 2014-12-22 | 2014-12-22 | |
| PCT/IB2015/059824 WO2016103146A1 (en) | 2014-12-22 | 2015-12-21 | Selective reduction of cysteine residues in il-17 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017008410A true MX2017008410A (es) | 2017-10-19 |
Family
ID=55135470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017008410A MX2017008410A (es) | 2014-12-22 | 2015-12-21 | Reduccion selectiva de residuos cisteina en anticuerpos il-17. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11292833B2 (es) |
| EP (2) | EP4389143A3 (es) |
| JP (3) | JP7021950B2 (es) |
| KR (2) | KR102643328B1 (es) |
| CN (4) | CN114316044A (es) |
| AR (1) | AR103172A1 (es) |
| AU (1) | AU2015370515B2 (es) |
| BR (1) | BR112017010069A2 (es) |
| CA (1) | CA2971541A1 (es) |
| IL (2) | IL298761A (es) |
| MX (1) | MX2017008410A (es) |
| PH (1) | PH12017500967A1 (es) |
| RU (2) | RU2719563C2 (es) |
| SG (1) | SG11201703639QA (es) |
| WO (1) | WO2016103146A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI763732B (zh) | 2016-11-07 | 2022-05-11 | 美商西雅圖遺傳學公司 | 工程化半胱胺酸帽之分佈 |
| CA3071852A1 (en) * | 2017-08-04 | 2019-02-07 | Amgen Inc. | Method of conjugation of cys-mabs |
| JP2021534151A (ja) * | 2018-08-15 | 2021-12-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 下流クロマトグラフィーにおける再酸化によるタンパク質断片化制御戦略 |
| CN109369806B (zh) * | 2019-01-14 | 2019-04-19 | 迈威(上海)生物科技有限公司 | 苏金单抗制品中半胱氨酸化变异体的去除方法 |
| EP4255927A1 (en) | 2020-12-02 | 2023-10-11 | Fresenius Kabi Deutschland GmbH | Methods of selectively reducing antibodies |
| CN116635416A (zh) | 2020-12-22 | 2023-08-22 | 诺华股份有限公司 | 用于在细胞培养期间降低分泌的重组表达蛋白质中半胱氨酸残基的氧化水平的方法 |
| CN113189184B (zh) * | 2021-04-28 | 2022-09-09 | 浙江大学 | 含有半胱氨酸的毛细管凝胶电泳样品缓冲液 |
| WO2023067626A1 (en) * | 2021-10-20 | 2023-04-27 | Dr. Reddy's Laboratories Limited | A cell culture process to produce an antibody composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4766205A (en) | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
| JP2669859B2 (ja) * | 1987-08-04 | 1997-10-29 | 協和醗酵工業株式会社 | タンパク質の再活性化法 |
| JP3610395B2 (ja) * | 1991-08-26 | 2005-01-12 | 敏一 中村 | 成熟肝実質細胞増殖因子 |
| CA2438094C (en) | 2001-02-23 | 2011-10-11 | Immunex Corporation | Increased recovery of active proteins |
| WO2003048357A1 (fr) * | 2001-12-04 | 2003-06-12 | Mitsubishi Pharma Corporation | Procede d'activation de proteine |
| JPWO2004056872A1 (ja) | 2002-12-20 | 2006-04-20 | 三菱ウェルファーマ株式会社 | タンパク質のチオール基を保護する方法 |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| US7928205B2 (en) | 2004-10-22 | 2011-04-19 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| EP2360170A3 (en) * | 2005-06-17 | 2012-03-28 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine |
| GB0513852D0 (en) * | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
| RU2430110C2 (ru) | 2006-01-31 | 2011-09-27 | Новартис Аг | Антитела - антагонисты интерлейкина-17 (ил-17) для лечения рака |
| ES2391657T3 (es) | 2006-02-07 | 2012-11-28 | Shire Human Genetic Therapies, Inc. | Composiciones estabilizadas de proteínas que tienen un resto tiol libre |
| KR20190140090A (ko) | 2007-07-09 | 2019-12-18 | 제넨테크, 인크. | 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지 |
| MX2010007767A (es) | 2008-01-18 | 2010-08-09 | Medimmune Llc | Anticuerpos manipulados con cisteina para conjugacion especifica de sitio. |
| CN102458479B (zh) * | 2009-06-04 | 2016-07-13 | 诺华公司 | 识别IgG结合位点的方法 |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| EP4137514A1 (en) | 2010-10-08 | 2023-02-22 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
| AU2014259523B2 (en) * | 2010-11-05 | 2016-02-04 | Novartis Ag | Methods of treating psoriatic arthritis using IL-17 antagonists |
| WO2012082573A1 (en) * | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
| JP5782279B2 (ja) | 2011-01-20 | 2015-09-24 | 株式会社Ｓｃｒｅｅｎホールディングス | 基板処理方法および基板処理装置 |
| EP2771364B1 (en) | 2011-10-27 | 2019-05-22 | Genmab A/S | Production of heterodimeric proteins |
| JP2015504430A (ja) | 2011-11-21 | 2015-02-12 | ノバルティス アーゲー | Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
-
2015
- 2015-12-18 AR ARP150104191A patent/AR103172A1/es unknown
- 2015-12-21 EP EP24170348.7A patent/EP4389143A3/en active Pending
- 2015-12-21 RU RU2017126025A patent/RU2719563C2/ru active
- 2015-12-21 MX MX2017008410A patent/MX2017008410A/es unknown
- 2015-12-21 KR KR1020177016755A patent/KR102643328B1/ko active IP Right Grant
- 2015-12-21 US US15/538,266 patent/US11292833B2/en active Active
- 2015-12-21 JP JP2017551390A patent/JP7021950B2/ja active Active
- 2015-12-21 CN CN202210002380.7A patent/CN114316044A/zh active Pending
- 2015-12-21 KR KR1020237038206A patent/KR20230159617A/ko active Application Filing
- 2015-12-21 SG SG11201703639QA patent/SG11201703639QA/en unknown
- 2015-12-21 BR BR112017010069A patent/BR112017010069A2/pt not_active Application Discontinuation
- 2015-12-21 CN CN202111452382.8A patent/CN114010780B/zh active Active
- 2015-12-21 EP EP15823803.0A patent/EP3237445A1/en active Pending
- 2015-12-21 CN CN201580066406.2A patent/CN107001460B/zh active Active
- 2015-12-21 IL IL298761A patent/IL298761A/en unknown
- 2015-12-21 IL IL251893A patent/IL251893B2/en unknown
- 2015-12-21 CN CN202210002418.0A patent/CN114249826B/zh active Active
- 2015-12-21 CA CA2971541A patent/CA2971541A1/en active Pending
- 2015-12-21 AU AU2015370515A patent/AU2015370515B2/en active Active
- 2015-12-21 RU RU2020113344A patent/RU2765307C2/ru active
- 2015-12-21 WO PCT/IB2015/059824 patent/WO2016103146A1/en active Application Filing
-
2017
- 2017-05-25 PH PH12017500967A patent/PH12017500967A1/en unknown
-
2022
- 2022-02-04 JP JP2022016666A patent/JP2022062194A/ja active Pending
- 2022-03-01 US US17/683,888 patent/US20220315650A1/en active Pending
-
2023
- 2023-06-01 JP JP2023091199A patent/JP2023110026A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500967A1 (en) | Selective reduction of cysteine residues in il-17 antibodies | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| PH12018501226A1 (en) | Methods for treating huntingtons disease | |
| BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| WO2016130704A3 (en) | Methods and compositions for analyzing cellular components | |
| MY176822A (en) | Anti-pd-1 antibody and use thereof | |
| MY192561A (en) | Taurine supplemented cell culture medium and methods of use | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| EA201690600A1 (ru) | Метаболически оптимизированная клеточная культура | |
| MX2017009767A (es) | Nuevas proteínas específicas para la angiogénesis. | |
| MX2018000897A (es) | Celulas madre hematopoyeticas que expresan pd-l1 y usos. | |
| MX2017013949A (es) | Composiciones mectantes a base de seda y sus metodos. | |
| BR112019003361A2 (pt) | métodos e usos de frações de material orgânico dissolvido para ligação a íons metálicos | |
| BR112018001511A2 (pt) | ?uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpo de isótipo igg1 ou igg4 humano | |
| MX2023014077A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
| BR112015014718A2 (pt) | métodos de uso de cromatografia de troca iônica para controlar níveis de glicoformas ricas em manose | |
| MA40371A (fr) | Sélectivité efficace des protéines recombinées | |
| MX2015010887A (es) | Formulaciones y metodos para aumentar la produccion de proteinas recombinantes. | |
| NZ742210A (en) | Neospora vaccine composition | |
| MX2019015499A (es) | Método para producir d-psicosa a partir de un complejo de borato y d-psicosa usando cromatografía y composición que contiene d-psicosa. | |
| MY191596A (en) | Igf-1r antibody and its use for the diagnosis of cancer |